{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:02:56Z","timestamp":1791471776406,"version":"4.3.4"},"reference-count":19,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Abrocitinib improved signs and symptoms of moderate\u2010to\u2010severe atopic dermatitis (AD) at 12 or 16\u2009weeks in phase 3 studies with a manageable safety profile. Further understanding of the abrocitinib long\u2010term efficacy and safety profile is important for its appropriate use in treating chronic AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the abrocitinib efficacy up to 48\u2009weeks and long\u2010term safety in patients with moderate\u2010to\u2010severe AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>JADE EXTEND (NCT03422822) is an ongoing, phase 3, long\u2010term extension study that enrolled patients from previous abrocitinib AD trials. This analysis focusses on patients from the phase 3 JADE MONO\u20101 (NCT03349060), JADE MONO\u20102 (NCT03575871) and JADE COMPARE (NCT03720470) studies who completed the full treatment period of placebo or abrocitinib (200\u2009mg or 100\u2009mg once daily) and subsequently entered JADE EXTEND. Efficacy endpoints included the proportion of patients achieving skin clearance (Investigator's Global Assessment [IGA] 0\/1 [clear\/almost clear]; \u226575% improvement in Eczema Area and Severity Index [EASI\u201075]) and itch response (Peak Pruritus Numerical Rating Scale [PP\u2010NRS] severity \u22654\u2010point improvement). Safety endpoints included treatment\u2010emergent adverse events (TEAEs), serious TEAEs and TEAEs leading to discontinuation. Data cut\u2010off: April 22, 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>As of the data cut\u2010off, ~70% and ~45% of patients received abrocitinib for \u226536 and \u226548\u2009weeks, respectively. Nasopharyngitis, atopic dermatitis, nausea and upper respiratory tract infections were the most frequent TEAEs. Serious TEAEs occurred in 7% and 5% and TEAEs leading to study discontinuation occurred in 9% and 7% of patients receiving abrocitinib 200\u2009mg and 100\u2009mg, respectively. Week 48 efficacy responses with abrocitinib 200\u2009mg and 100\u2009mg were as follows: IGA 0\/1 52% and 39%; EASI\u201075 82% and 67%, and PP\u2010NRS severity \u22654\u2010point improvement 68% and 51%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with moderate\u2010to\u2010severe AD, long\u2010term abrocitinib treatment resulted in clinically meaningful skin and pruritus improvement. The long\u2010term safety profile was manageable and consistent with previous reports.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.19280","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T14:43:05Z","timestamp":1687185785000},"page":"2056-2066","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Abrocitinib efficacy and safety in patients with moderate\u2010to\u2010severe atopic dermatitis: Results from phase 3 studies, including the long\u2010term extension JADE EXTEND study"],"prefix":"10.1111","volume":"37","author":[{"given":"Kristian","family":"Reich","sequence":"first","affiliation":[{"name":"University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"},{"name":"MoonLake Immunotherapeutics AG  Zug Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7805","authenticated-orcid":false,"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"The George Washington University School of Medicine &amp; Health Sciences  Washington District of Columbia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-3642","authenticated-orcid":false,"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[{"name":"Alliance Clinical Trials and Probity Medical Research  Waterloo Ontario Canada"},{"name":"The University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0593-9925","authenticated-orcid":false,"given":"Mette","family":"Deleuran","sequence":"additional","affiliation":[{"name":"Aarhus University Hospital  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norito","family":"Katoh","sequence":"additional","affiliation":[{"name":"Kyoto Prefectural University of Medicine  Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-2057","authenticated-orcid":false,"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[{"name":"Yale University  New Haven Connecticut USA"},{"name":"Central Connecticut Dermatology  Cromwell Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8452-667X","authenticated-orcid":false,"given":"Lisa A.","family":"Beck","sequence":"additional","affiliation":[{"name":"University of Rochester Medical Center  Rochester New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"de Bruin\u2010Weller","sequence":"additional","affiliation":[{"name":"UMC Utrecht  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Werfel","sequence":"additional","affiliation":[{"name":"Hannover Medical School  Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Groton Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinaki","family":"Biswas","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco D.","family":"DiBonaventura","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Chan","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Groton Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Johnson","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Raleigh\u2010Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleem A.","family":"Farooqui","sequence":"additional","affiliation":[{"name":"Pfizer R&amp;D UK Ltd.  Sandwich Kent UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urs","family":"Kerkmann","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Clibborn","sequence":"additional","affiliation":[{"name":"Pfizer Ltd.  Tadworth Surrey UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0001-z"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.10.039"},{"key":"e_1_2_10_4_1","volume-title":"CIBINQO (abrocitinib) tablets, for oral use [prescribing infromation]","author":"Pfizer Inc","year":"2022"},{"key":"e_1_2_10_5_1","volume-title":"Cibinqo 100 mg film\u2010coated tablets (summary of product characteristics)","author":"Pfizer Limited","year":"2021"},{"key":"e_1_2_10_6_1","volume-title":"CIBINQO\u00ae (abrocitinib). Summary of product characteristics (SmPC)","author":"European Medicines Agency","year":"2021"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30732-7"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.1406"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2019380"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2830"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00618-3"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17744"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.0029"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.07.036"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16948"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.1273"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802215315"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00639-y"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12583"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19751"}],"updated-by":[{"DOI":"10.1111\/jdv.19563","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000}}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.19280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T09:16:42Z","timestamp":1711012602000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.19280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1111\/jdv.19280"],"URL":"https:\/\/doi.org\/10.1111\/jdv.19280","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]},"assertion":[{"value":"2023-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}